Health Insurance 101: Helping Patients Navigate the Health Insurance Maze

Patients often rely on their healthcare provider to be a resource for answering questions related to health insurance coverage, but education on this topic is not included in most graduate medical education curricula. Providers need to be aware of the myriad insurance-related issues they may encounter and understand how they can help their patients navigate potential coverage landmines and advocate for themselves to ensure the best care possible.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, PAs, pharmacists, social workers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe different insurance types (e.g., Medicare, Medicaid, Affordable Care Act) and how coverage can affect patients with cancer and the treatment they receive.
  • Discuss potential insurance-related barriers (e.g., uninsured, denial letters, high co-pays, deductibles) and how to address them.
  • Identify advocacy organizations and members of the interprofessional oncology care team that help patients navigate health insurance issues.

You may also be interested in

Plenary Session - Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care
Cancer drug shortages have had a significant impact on clinical practice with much confusion around how to appropriately manage care of patients with cancer in the midst of a drug shortage. You can benefit by learning what you can do both in your practice and in your advocacy to advance short-term and long-term solutions.
Changing Economics in Cancer Care: Optimizing Resources and Strategic Tactics to Improve Patient Outcomes and Protect the Workforce
Understanding the changes in the economics of oncology care and the increasing financial challenges impacting cancer centers is important for stakeholders at all levels to become informed consumers of the healthcare system. It is important for cancer center leaders to have this information to make informed decisions around resource allocation for continued viability.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; BeiGene; Coherus BioSciences; Genentech, a member of the Roche Group; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by independent medical educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Course opens: 
06/15/2024
Course expires: 
03/01/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Oncology Fellows Program: New Horizons in Quality Cancer Care™

Moderator

Randall A. Oyer, MD
Penn Lancaster

Panelists

Karen Costello, MSS, LSW, OSW-C
Cancer Support Community
    
Carmen E. Guerra, MD, MSCE
Abramson Cancer Center at the University of Pennsylvania
    
Heather Jones, PharmD, MS
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and 
Cleveland Clinic Taussig Cancer Institute
    
Bryan Loy, MD, MBA
Humana

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty, Moderator, and Planner Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose. 

Karen Costello, MSS, LSW, OSW-C
Karen Kanefield
Wui-Jin Koh, MD
Heather Jones, PharmD, MS
Bryan Loy, MD, MBA
Randall A. Oyer, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Carmen E. Guerra, MD, MSCE
Genentech, Inc.: Grant/Research Support
Guardant Health: Scientific Advisor

Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Scientific Advisor

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP 
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-24-081-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 1, 2025. PAs should only claim credit commensurate with the extent of their participation.

Social Workers
As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 1.25 continuing education credits.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing